COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

5.51%

Increased from previous period

Growth of 5.51% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

7.49%

Increased from previous period

Cost growth of 7.49% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.

Gross Profit Growth

-2.33%

Increased from previous period

Gross profit decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.

Gross Margin Ratio Growth

-7.43%

Decreased from previous period

Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

-6.00%

Decreased from previous period

Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

-1.33%

Decreased from previous period

Operating expenses reduction while Medical - Pharmaceuticals median is 0.08%. Seth Klarman would investigate advantages.

Total Costs & Expenses Growth

6.07%

Increased from previous period

Total costs change of 6.07% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.

Interest Expense Growth

No Data

No Data available this quarter, please select a different quarter.

Depreciation & Amortization Growth

-5.91%

Decreased from previous period

D&A reduction while Medical - Pharmaceuticals median is 0.79%. Seth Klarman would investigate efficiency.

EBITDA Growth

-4.92%

Increased from previous period

EBITDA decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

EBITDA Margin Growth

-9.89%

Increased from previous period

EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

Operating Income Growth

-5.57%

Increased from previous period

Operating income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

Operating Margin Growth

-10.51%

Increased from previous period

Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

Other Income/Expenses Growth

2.64%

Decreased from previous period

Other expenses change of 2.64% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.

Pre-Tax Income Growth

-4.93%

Increased from previous period

Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

Pre-Tax Margin Growth

-9.90%

Increased from previous period

Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

-4.57%

Increased from previous period

Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.

Net Income Growth

-5.25%

Increased from previous period

Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

Net Margin Growth

-10.20%

Increased from previous period

Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

EPS Growth

-5.25%

Increased from previous period

EPS decline while Medical - Pharmaceuticals median is 3.22%. Seth Klarman would investigate causes.

Diluted EPS Growth

-5.25%

Increased from previous period

Diluted EPS decline while Medical - Pharmaceuticals median is 2.40%. Seth Klarman would investigate causes.

Share Count Growth (Basic)

-0.00%

Share count reduction while Medical - Pharmaceuticals median is 0.23%. Seth Klarman would investigate strategy.

Share Count Growth (Diluted)

-0.00%

Diluted share reduction while Medical - Pharmaceuticals median is 0.12%. Seth Klarman would investigate strategy.

Select Chart Metric:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

5.51%

Increased from previous period

Growth of 5.51% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

7.49%

Increased from previous period

Cost growth of 7.49% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.

Gross Profit Growth

-2.33%

Increased from previous period

Gross profit decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.

Gross Margin Ratio Growth

-7.43%

Decreased from previous period

Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

-6.00%

Decreased from previous period

Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

-1.33%

Decreased from previous period

Operating expenses reduction while Medical - Pharmaceuticals median is 0.08%. Seth Klarman would investigate advantages.

Total Costs & Expenses Growth

6.07%

Increased from previous period

Total costs change of 6.07% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.

Interest Expense Growth

No Data

No Data available this quarter, please select a different quarter.

Depreciation & Amortization Growth

-5.91%

Decreased from previous period

D&A reduction while Medical - Pharmaceuticals median is 0.79%. Seth Klarman would investigate efficiency.

EBITDA Growth

-4.92%

Increased from previous period

EBITDA decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

EBITDA Margin Growth

-9.89%

Increased from previous period

EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

Operating Income Growth

-5.57%

Increased from previous period

Operating income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

Operating Margin Growth

-10.51%

Increased from previous period

Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

Other Income/Expenses Growth

2.64%

Decreased from previous period

Other expenses change of 2.64% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.

Pre-Tax Income Growth

-4.93%

Increased from previous period

Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

Pre-Tax Margin Growth

-9.90%

Increased from previous period

Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

-4.57%

Increased from previous period

Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.

Net Income Growth

-5.25%

Increased from previous period

Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

Net Margin Growth

-10.20%

Increased from previous period

Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.

EPS Growth

-5.25%

Increased from previous period

EPS decline while Medical - Pharmaceuticals median is 3.22%. Seth Klarman would investigate causes.

Diluted EPS Growth

-5.25%

Increased from previous period

Diluted EPS decline while Medical - Pharmaceuticals median is 2.40%. Seth Klarman would investigate causes.

Share Count Growth (Basic)

-0.00%

Share count reduction while Medical - Pharmaceuticals median is 0.23%. Seth Klarman would investigate strategy.

Share Count Growth (Diluted)

-0.00%

Diluted share reduction while Medical - Pharmaceuticals median is 0.12%. Seth Klarman would investigate strategy.

Select Chart Metric: